IRADIMED Insider Sale: 5,000 Shares Disposed Under 10b5-1 Plan

Rhea-AI Filing Summary

Roger E. Susi, CEO, President and Chairman of IRADIMED CORP (IRMD) reported a sale of 5,000 shares of the company on 09/23/2025 under a Rule 10b5-1 trading plan adopted on 06/16/2025. The weighted average sale price was $71.2581, with individual trade prices ranging from $70.81 to $71.61. After the transaction the filing reports total beneficial ownership of 2,352,500 shares, held indirectly through family and revocable trusts; two other trust positions of 162,950 and 2,062,500 shares are disclosed. The reporting person disclaims beneficial ownership except to the extent of pecuniary interest. The Form 4 is signed and dated 09/24/2025.

Positive

• Sale executed under a Rule 10b5-1 trading plan, indicating pre-arranged compliance with insider trading rules
• Detailed pricing disclosure provided: weighted average price $71.2581 and price range $70.81–$71.61
• Clear identification of indirect ownership through named trusts and an explicit disclaimer of broader beneficial ownership

Negative

• Insider disposition reported—5,000 shares were sold on 09/23/2025
• Form does not state total company shares outstanding, so relative scale of the holdings versus total float is not provided

Insights

Securities Analyst

TL;DR: Insider sale of 5,000 shares under a pre-arranged 10b5-1 plan; large indirect holdings remain.

The sale reported on 09/23/2025 was executed pursuant to a Rule 10b5-1 plan adopted 06/16/2025, indicating it was pre-planned rather than opportunistic trading. The filing provides the weighted average sale price of $71.2581 and notes trade prices ranged $70.81–$71.61. The report shows substantial beneficial ownership positions held indirectly through multiple trusts totaling several million shares, and the filer disclaims beneficial ownership beyond pecuniary interest. For investors, this is a routine disclosure of an insider liquidity event under an established plan rather than an unscheduled disposition.

Corporate Governance Expert

TL;DR: Disclosure follows standard Section 16 practice; trusts and disclaimers are clearly stated.

The Form 4 documents compliance with Section 16 reporting: the transaction code S(1) is explained as executed under a 10b5-1 plan, and the filer offers to provide detailed trade-by-trade information upon request. Indirect ownership is explicitly identified as held "By Phillip Susi 2008 Dynasty Trust," "By Roger E. Susi Revocable Trust," and "By Matthew Susi 2008 Dynasty Trust," with an explicit disclaimer of broader beneficial ownership. The filing is signed and dated, meeting formal signature requirements. Materiality is limited to the reported sale amount and the ownership disclosures included.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Susi Roger E.

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, PRESIDENT, CHAIRMAN

3. Date of Earliest Transaction (Month/Day/Year)
09/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/23/2025		S(1)		5,000	D	$71.2581(2)	2,352,500(3)	I	By Phillip Susi 2008 Dynasty Trust
Common Stock								162,950	I	By Roger E. Susi Revocable Trust
Common Stock								2,062,500(3)	I	By Matthew Susi 2008 Dynasty Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

2. This transaction was executed in multiple trades at prices ranging from $70.81 to $71.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Roger E. Susi	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Roger E. Susi report on Form 4 for IRMD?

He reported a sale of 5,000 shares on 09/23/2025 executed under a Rule 10b5-1 plan; weighted average sale price was $71.2581.

When was the 10b5-1 trading plan adopted for the reported sale?

The plan was adopted on 06/16/2025, as stated in the Form 4 explanation.

How many IRMD shares does the filing show beneficially owned after the sale?

Total beneficial ownership reported is 2,352,500 shares, held indirectly through trusts.

What price range did the reported trades execute at?

Individual trades occurred between $70.81 and $71.61; the weighted average price reported is $71.2581.

Does the reporting person claim full beneficial ownership of the disclosed shares?

No; the filing states the reporting person disclaims beneficial ownership except to the extent of pecuniary interest.